New Clinical Analysis Spotlights Side Effect Burden Across Ketamine Formats
A new review published in Psychiatric Times is making rounds in treatment-resistant depression (TRD) circles — and for good reason. The piece examines the side effect profiles and discontinuation rates of NMDA receptor antagonists, the drug class that includes both IV ketamine and intranasal esketamine (Spravato), and calls on clinicians to use outcomes data more aggressively to guide treatment decisions. The core message: optimize doses faster, switch agents sooner when tolerability is an issue, and track standardized metrics like PHQ-9 scores and side effect burden to reach remission without unnecessary delays.
For patients using ketamine troches at home as part of a broader treatment protocol, this analysis carries specific and actionable implications. The side effect conversation around ketamine often defaults to the IV infusion experience — but troches operate on a fundamentally different pharmacokinetic curve, and understanding that difference helps patients and providers make smarter decisions about format, dose, and duration.
Why Delivery Format Changes the Side Effect Equation
When clinicians discuss NMDA antagonist side effects, the most commonly cited concerns are dissociation, perceptual disturbances, dizziness, nausea, and transient blood pressure elevation. These effects are real and well-documented — but their intensity and clinical significance vary considerably depending on how ketamine enters the body and how quickly it does so.
IV ketamine infusions deliver the drug directly into the bloodstream over 40 minutes, producing peak plasma concentrations that are rapid and relatively high. That fast rise is clinically useful for rapid-onset antidepressant effects, but it's also the primary driver of dissociative intensity and the cardiovascular monitoring requirements that make infusions a clinical-setting-only treatment. Intranasal esketamine (Spravato) follows a similar logic — bioavailability is faster than oral routes, and the two-hour post-dose monitoring requirement under its REMS program reflects that reality.
Ketamine troches — sublingual or buccal lozenges — work differently. Absorption is slower and more variable, with peak plasma concentrations typically lower than IV and onset more gradual. This pharmacokinetic profile generally translates to a milder dissociative experience for most patients, which is a meaningful tolerability advantage. Nausea is reported but tends to be less acute than with infusions. The cardiovascular effects are present but more modest at therapeutic troche doses. For patients with anxiety around dissociation or those who have discontinued IV infusions due to side effect burden, the troche format often represents a viable and more sustainable path forward.
This doesn't mean troches are side-effect-free. Dissociation, even at lower intensity, requires a safe set and setting. Cognitive blunting on dosing days is common. Some patients report lingering fatigue or emotional rawness following sessions. And the at-home nature of troche treatment shifts the monitoring responsibility from a clinical team to the patient and, ideally, a support person — which underscores the importance of good intake protocols and regular check-ins with prescribing providers.
Discontinuation Rates: What the Data Tells Us About Staying in Treatment
The Psychiatric Times review emphasizes discontinuation rates as a key, underappreciated metric in TRD care. High discontinuation — patients stopping treatment before reaching remission — is a persistent problem across antidepressant classes, and NMDA antagonists are not immune. For esketamine, real-world discontinuation data have been mixed: the in-office requirement creates logistical friction that leads some patients to drop out before the treatment has time to work. For IV ketamine, cost and access barriers drive discontinuation independent of side effect experience.
Troches occupy an interesting position in this conversation. On one hand, at-home administration removes the logistical barrier that pushes patients away from clinic-based options. On the other hand, the lack of mandatory monitoring means side effects that would be caught and managed in a clinical setting can go unaddressed — and in some cases, a difficult or frightening experience at home can lead patients to self-discontinue before they've discussed it with their provider.
The review's call for faster dose optimization and earlier switching is directly relevant here. In practice, many patients on troches start conservatively — which is appropriate — but stay at a sub-therapeutic dose for too long because follow-up appointments are infrequent or because patients are hesitant to report that they're not feeling better. The data increasingly support a more proactive approach: structured symptom tracking between sessions, willingness to adjust dose within the first four to six weeks if response is incomplete, and explicit conversations about what side effects are expected versus what warrants pausing treatment.
PHQ-9 tracking, specifically mentioned in the review as a key metric, is something every troche patient should be doing. It provides objective data that can anchor provider conversations, demonstrate treatment response over time, and flag early warning signs if mood worsens. Many telehealth ketamine platforms now build this into their follow-up workflows, but patients who use more traditional prescribing arrangements should proactively request it.
Key Takeaway for Troche Patients
Troches generally produce a milder side effect profile than IV ketamine or esketamine nasal spray due to slower, lower-peak absorption — but tolerability is not the same as absence of effects. If you've experienced side effects that led you to skip doses or consider stopping, bring that conversation to your provider before discontinuing. Dose adjustments, timing changes, and preparation strategies (anti-nausea measures, anxiety management, intentional set and setting) can address most common troche side effects without abandoning treatment. Use a PHQ-9 or equivalent tool at every check-in to give your provider objective data for decisions about dose optimization or format switching.
What This Means for Your Treatment Workflow
The broader takeaway from this review is one of urgency and precision. Treatment-resistant depression is, by definition, a condition that has already failed multiple prior treatments. Every unnecessary delay — whether from undertreated side effects, slow dose escalation, or reluctance to switch formats when one isn't working — represents additional time spent in a depressive episode. The data are now robust enough to support a more decisive clinical posture.
For patients on ketamine troches, this translates to a few concrete actions. First, if side effects from your current dose or protocol are affecting your willingness to dose consistently, treat that as a clinical problem to be solved, not a reason to quietly stop. Second, if you've been on troches for six or more weeks without meaningful symptom improvement, ask your provider directly whether your dose needs adjustment or whether an alternative format — IV boosters, a course of esketamine, or a different ketamine protocol — might be warranted. Third, standardize your outcome tracking. Side effect journals and PHQ-9 scores give your provider the signal they need to make data-driven decisions on your behalf.
The NMDA antagonist class, troches included, offers a genuinely different mechanism of action from standard antidepressants — and for many patients, it represents the best shot at remission after years of treatment failures. Getting the format, dose, and monitoring right is what determines whether that shot lands. Read the full review in Psychiatric Times.
Share